SCHEMBL3206422

SCHEMBL3206422

Cc1ccccc1S(=O)(=O)NC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.55
SLC1A2 P43004 1/20 0.55
SLC1A1 P43005 1/20 0.55
ALKBH2 Q6NS38 1/20 0.55
ALKBH3 Q96Q83 1/20 0.55
CA1 P00915 5/20 0.54
CA2 P00918 5/20 0.54
CA9 Q16790 5/20 0.54
LMNA P02545 2/20 0.50
FBP1 P09467 1/20 0.50
KAT6A Q92794 1/20 0.50
CA12 O43570 3/20 0.49
ITGAV P06756 1/20 0.49
ALDH1A1 P00352 3/20 0.49
RXFP1 Q9HBX9 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PKM P14618 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
TP53 P04637 1/20 0.46
KDM4E B2RXH2 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL9178383 0.94 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL3548718 0.86 CA1 (0.52) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL3637063 0.85 LMNA (0.68) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL29489589 0.85 CA1 (0.55) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL6723764 0.85 CA1 (0.51) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL11337623 0.85 CA1 (0.51) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL3548714 0.85 CA1 (0.51) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL6465947 0.85 CA1 (0.55) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL11337626 0.85 CA1 (0.51) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3
SCHEMBL13329854 0.83 CA1 (0.50) SLC1A3SLC1A2SLC1A1ALKBH2ALKBH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0542556-B1 Thermosensitive recording material NEW OJI PAPER CO LTD (JP) 1995-07-19 EP claimed
CN-105017172-B A kind of oxazine compounds of 2 carbonyl of halogen photolytic activity 1,3 and preparation method and application 中国科学院化学研究所 2017-07-14 CN disclosed
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
EP-1499305-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES Pfizer Japan Inc. (JP) 2005-01-26 EP disclosed
WO-2003086371-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 SLC1A3 1095/4885SLC1A2 1024/4885SLC1A1 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.